{"name":"Targeted Medical Pharma","slug":"targeted-medical-pharma","ticker":"","exchange":"","domain":"","description":"Targeted Medical Pharma is a specialty pharmaceutical company focused on developing and commercializing medical foods and drugs for the treatment of chronic pain and other neurological conditions. The company has a portfolio of marketed products and is actively engaged in research and development to expand its therapeutic offerings.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5260941,"revenueGrowth":-26,"grossMargin":0,"rdSpend":12317,"netIncome":-3043810,"cash":2427110,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Theraprofen","genericName":"Theraprofen","slug":"theraprofen","indication":"Other","status":"marketed"},{"name":"ESS (medical food/drug)","genericName":"ESS (medical food/drug)","slug":"ess-medical-food-drug","indication":"Other","status":"phase_3"},{"name":"Placebo trazodone and placebo Sentra PM","genericName":"Placebo trazodone and placebo Sentra PM","slug":"placebo-trazodone-and-placebo-sentra-pm","indication":"Control arm in Phase 3 clinical trial (active indications unknown without trial protocol)","status":"phase_3"},{"name":"Theramine","genericName":"Theramine","slug":"theramine","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Active Theramine and Active Naproxen","genericName":"Active Theramine and Active Naproxen","slug":"active-theramine-and-active-naproxen","indication":"Neuropathic pain conditions","status":"phase_3"}]}],"pipeline":[{"name":"Theraprofen","genericName":"Theraprofen","slug":"theraprofen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Active Theramine and Active Naproxen","genericName":"Active Theramine and Active Naproxen","slug":"active-theramine-and-active-naproxen","phase":"phase_3","mechanism":"This combination product delivers active B-vitamin complex (Theramine) alongside the nonsteroidal anti-inflammatory drug naproxen to provide pain relief with nutritional support.","indications":["Neuropathic pain conditions","Inflammatory pain with nutritional deficiency"],"catalyst":""},{"name":"ESS (medical food/drug)","genericName":"ESS (medical food/drug)","slug":"ess-medical-food-drug","phase":"phase_3","mechanism":"ESS is a medical food/drug formulation designed to provide specialized nutritional support, likely targeting metabolic or gastrointestinal dysfunction.","indications":[],"catalyst":""},{"name":"Placebo trazodone and placebo Sentra PM","genericName":"Placebo trazodone and placebo Sentra PM","slug":"placebo-trazodone-and-placebo-sentra-pm","phase":"phase_3","mechanism":"This is a placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.","indications":["Control arm in Phase 3 clinical trial (active indications unknown without trial protocol)"],"catalyst":""},{"name":"Theramine","genericName":"Theramine","slug":"theramine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQY19HcWc3Z3BES3NYVndSZ2luREpub04zdGRXZnJIa1JKYmdyM2dGQjdWTTREeTBwNGNJQmh5YTZjOGJPTnByaVdUY2hXbXZydnZSSkRUUkF3YlRxUEJubTBSaUZZbmhvdEZzUDNvZWgxNVlXY0VsYkJJNW0tSkFwZm9mQzdvSjdrUUMwcVlHSDdKVmVrMmxnc2dodjVvM2FQb0tDMUZlQ3VwdC15UWJua21yUm13dmFwOWhYMEdIN3o5WEdxQ3JfV1ZNRjh5OWZEbmlwUk91dUYzOGJKUFN2Vmhhc2FaT2VsOW1aQUtraEUydw?oc=5","date":"2026-03-02","type":"deal","source":"PR Newswire","summary":"Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs - PR Newswire","headline":"Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNZFV4M0RGSnd0a3BBejZOd1IyTDVTck80WHFGNTl6eHBMdDlFa3ltbDNHREJCdTFNT1dMVVd6S0U4a3MwNGlZUVFNN28tWnRtNlRBVXBreFFIOVFvUDhaMjctUlFDanJld21VTzZSS2tCMkViQ3pvNFVXOWNENWExTWNtdjBBbjVFVHF4WFVXNUljN28?oc=5","date":"2026-02-23","type":"regulatory","source":"statnews.com","summary":"Pharma lobbyists focus on a surprising new target: the FDA - statnews.com","headline":"Pharma lobbyists focus on a surprising new target: the FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxNTnN4MEhDV3U1YURYdVZIeHNZT29jVV8waGdyRjJvX0E5YkR0eUwzLTVPVlJTcEVOaGRQbXlfWmdVSlRKc3pnNHpKQUlXNFVnU0dUMDhpMjd2U2RtQkZSV1RSbFR1UjE2ei1SZHpiZ0plS1FkSDZ3blRnR0tuaW95NlR1TlJ3Z3g5Q05RdTgtTTNCRGNJOWdVT3dxTXJOYmItMUhlTHZ6eWExME9QdWJ6Uk8zMnNOdDI4T3pRb2xnOVpLbF9rSGVTNW54QzIzc0ltZUNFSjlTNUx1ckd0WWhxUUlSNk52czZaWXZsSHZEd1hJM1NKWGI0ZG9LYUdCbmFZMUN3U0hBa3hCWjRacGhKdGZKWGlyYmpCckFOSk1XZHJkNlF2UTJXSVdlWEs0VHZZTVI0UjRWSk56WWFlcEtv?oc=5","date":"2026-01-26","type":"regulatory","source":"2 Minute Medicine","summary":"Oral gonorrhea antibiotic Nuzolvence approved just weeks ago - 2 Minute Medicine","headline":"Oral gonorrhea antibiotic Nuzolvence approved just weeks ago - 2 Minute Medicine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOdWE2ZmxUV1pOdXp4TFJJbHJCZzFNUTFKamVWbGRHU3JER0FsUTk0Y2xDY1FFczMwdHdrYVh0VjJqcmx4VWk2dGVoZ1ZVUHpUTVNYd1dSR2k3WDVmZEo0QkdTLTRsZXFuMEhJUkpHWnF0Tm5neEQyYVcyakxScDQxakJHcWFkLTdHUmlEWA?oc=5","date":"2025-11-04","type":"regulatory","source":"Fierce Pharma","summary":"On a roll, UCB picks up another rare disease FDA approval - Fierce Pharma","headline":"On a roll, UCB picks up another rare disease FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE53VHVHSXcwdU1qUUhyVU1KUzVyMnkxbGxCRnVLT09yYnA5VE5pRWQ1emFNdnVVd1hoS09mQ0VDa3dOYWVfLVVJOGJ1OFRmcEMteTFYOXFIUkZlQVgt?oc=5","date":"2025-10-21","type":"pipeline","source":"EurekAlert!","summary":"Insilico Pharma.AI fall launch recap: Understand latest AI updates for healthcare research with frequent questions answered - EurekAlert!","headline":"Insilico Pharma.AI fall launch recap: Understand latest AI updates for healthcare research with frequent questions answe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQa0tXTFpLWTBxT2gxbXpabWtFVTcwQnFVQ2JyM3VoU09XTjBEQjhXOFFRMUU5dUFxODF1bGM1U3lyRktkMWRNdkpoQnhzRlItLVFCT1U4eXVmSUpEQXk4WUZudFhHVVp4Y01fRlBhQWZ4NzFaajlZaGxBSDNzc29vblo2aVREaUFVYjFZVHNPWmxERnBhclByQjJCelVCSzEteFdFMVlqaHJXUG0zVzcyb1NWZFFLTktMd2NETUM0RVVnSDc3ZGw4YzFLTQ?oc=5","date":"2025-10-08","type":"pipeline","source":"News-Medical","summary":"Aptamer expands into targeted radiopharmaceuticals with major top 3 pharma contract - News-Medical","headline":"Aptamer expands into targeted radiopharmaceuticals with major top 3 pharma contract - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNSkpGdl9sZnExeXVqOWRyb0ppWllkR2ZEeDZCNzdpZHhhc3FtQ0wyVTJGRlBaRjJrb2tJTU9vNFZaOTA4ZlpyZWRIMzlJUzY3a3VsWndleTBBZzZnNEFOaEdrX0w4bW1rX3E5em8zT01hTlJaazMwTHFGVWFKZUg0MXVWQUZORnhRcHdRZG9qZ3NWdGVTajRnMnBiaC1DSk9nbmVHNFBKS041ZDlINzNYX215TDZON2p1NlhoYWQyZ0ZFaXV5NDRZdHNyeFRrSlI5LV9scE9GUQ?oc=5","date":"2025-10-02","type":"deal","source":"Reuters","summary":"Exclusive: Trump targets deals in pharma, AI, energy, mining before midterm elections - Reuters","headline":"Exclusive: Trump targets deals in pharma, AI, energy, mining before midterm elections","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNbzJBOWoteEk2TDEybDJwUHl1cEFsYS1EcnZUaE55SzFYUUp6cVJ4MmJiOUJRTG1FaXpnUEZSby1ZNW9KMFhBM1d4S2l4UHhmVGRjem8yc09sSWJUUTZTTlRsNFRTUVh5Mzl4YURrTVhjRExLczBlaTRtam1ITmJZWldxOFVJYzBmQXVFekpYcW93aUVjN1BGcDRfbG1QRExpbVBsRmh4VXB5RkZ5ZzNEdmdMcV9ZcGc2VXhydWlvU2Y?oc=5","date":"2025-06-02","type":"pipeline","source":"Reuters Events","summary":"Precision Medicine: Transforming Cancer Treatment Through Targeted Therapies - Reuters Events","headline":"Precision Medicine: Transforming Cancer Treatment Through Targeted Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQMDVUQkVHOTJPdGhxUE1yUjJKaU5ObTM1dnZvVWJPamVGOWVQbkdmaDdnQkhDYWhaS25uOFF4OVdBSGlWQnhkQVVra1MwajJscDBYTWpQOFFhR3NYNjljcDhzbzg1M3UtQThURGJrbTJ2bzZjWXhibjVwaDJCS0QzUFMxMHFaRDZ2ekoyTkk1c2hmUDEzQnhJUmRRdzZXYy0tem50T21ST2J2SzBuNkdKYQ?oc=5","date":"2025-04-30","type":"pipeline","source":"WSJ","summary":"Drugmakers Have Spent Millions Targeting ‘Middlemen’—and It’s Paying Off - WSJ","headline":"Drugmakers Have Spent Millions Targeting ‘Middlemen’—and It’s Paying Off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPRXI2cElqV3Z4WFBBR1ItRTgxQ1hqcTNNNGNycjc2MUwyclF5X1BSZVpHYUxJdk02aXV5OGV2T19fUnlMbU0tUjM4bDJkTHVGNjJjMm12T1lvUU1hVFZxTHdoOVRCUXAzYXFYVGI5cnAxM3BoRTNKcUtRUld2LVk1LVBKY0N1WUpLU0Vad0lZeWJRbGZwZVAtbXRNZ3BfZHBzZldxVFBWNlB1allDY1E5dWlBakxXLW9fZDRZMUlKcHRSZw?oc=5","date":"2025-01-22","type":"pipeline","source":"McKinsey & Company","summary":"Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company","headline":"Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOSzNiMzJWMHo3SHpldGw3aWhtaGpIYXAyWEEzV1JZbnhyb0VEUGZtLUI0WGthcmZaZlJGdHlRYTNmc3hDRG9SWUlzRG9ydWdJM1h2eWdTUXhGMGQwQ3VNcXhOdDhWV3YtdTBhNHVsSHB3Ry1Qa2xMMHZYQTJlbFB0YmRVUHRIanBxbndFajNmbw?oc=5","date":"2024-10-11","type":"pipeline","source":"Pharmaceutical Executive","summary":"Amazon Targeting the Transactional in the Pharma Market - Pharmaceutical Executive","headline":"Amazon Targeting the Transactional in the Pharma Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKR3QweVdNTHZOaG9oNzQxNEZVemxOV2N5V2Q1aXdpUU5WbTlQTW9LcEFFamV0RUs4M1k2TUNBQk1UOXBROXRtbkhPWWVSajBpQWR6aUlqM1ZFeG05MHhDamt5ZjJUUQ?oc=5","date":"2024-01-19","type":"regulatory","source":"Straits Research","summary":"Medical Foods Market Size, Top Share, Demand And Regional Analysis by 2033 - Straits Research","headline":"Medical Foods Market Size, Top Share, Demand And Regional Analysis by 2033","sentiment":"neutral"},{"date":"2019-05-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2019-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2017-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_3":3},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5260941,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":5260941,"period":"2015-12-31"},{"value":7112359,"period":"2014-12-31"},{"value":7112359,"period":"2014-12-31"},{"value":9555562,"period":"2013-12-31"},{"value":9555562,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12317,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-3043810,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2427110,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}